Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 4601–4650 of 33076
John T. Jimenez, who has served as Chief Financial Officer of the Company since 2021, intends to retire from the Company
Gregory J. Hayes, RTX’s current Executive Chairman, has informed the Board of Directors of his intention to not stand for re-election and to step down as Executive Chairman and as a member of the Board, effective April 30, 2025.
the following individuals, each of whom was a member of the board of directors of HTLF immediately prior to the Effective Time, were appointed to the board of directors of UMB: John Schmidt, Brad Henderson, Jennifer Hopkins, Margaret Lazo and Susan Murphy.
the following individuals, each of whom was a member of the board of directors of HTLF immediately prior to the Effective Time, were appointed to the board of directors of UMB: John Schmidt, Brad Henderson, Jennifer Hopkins, Margaret Lazo and Susan Murphy.
the following individuals, each of whom was a member of the board of directors of HTLF immediately prior to the Effective Time, were appointed to the board of directors of UMB: John Schmidt, Brad Henderson, Jennifer Hopkins, Margaret Lazo and Susan Murphy.
the following individuals, each of whom was a member of the board of directors of HTLF immediately prior to the Effective Time, were appointed to the board of directors of UMB: John Schmidt, Brad Henderson, Jennifer Hopkins, Margaret Lazo and Susan Murphy.
the following individuals, each of whom was a member of the board of directors of HTLF immediately prior to the Effective Time, were appointed to the board of directors of UMB: John Schmidt, Brad Henderson, Jennifer Hopkins, Margaret Lazo and Susan Murphy.
On January 30, 2025, Jeffrey Landau, Senior Vice President, Chief Business Officer, and Head of Strategy, of CytomX Therapeutics, Inc. (the “Company”) and the Company agreed that Mr. Landau’s employment by the Company would terminate, effective February 7, 2025.
the date that Wissam G. Jabre will cease to be the Company’s Chief Financial Officer
On January 30, 2025, Reuben Jeffery III notified Affiliated Managers Group, Inc. (“AMG”) of his decision to retire from the Board of Directors (the “Board”), effective immediately.
Mr. Hurlston will succeed Alan Lowe, the Company’s President and Chief Executive Officer, who is stepping down as President and CEO effective as of immediately prior to 12:00 a.m. Pacific Time on February 7, 2025.
Pursuant to the Plan, effective as of the close of business on the Effective Date, Carlos A. de Solo, Kevin Berg, Edward J. Borkowski, Bryan Cho, Ralph De La Torre, M.D., Dr. Vincent Omachonu, Ryan O’Quinn and Jose R. Rodriguez ceased to be directors of the Company.
In addition, effective as of the close of business on the Effective Date, Carlos de Solo, Chief Executive Officer of the Company, Alberto de Solo, Chief Operating Officer of the Company, Kevin Wirges, Chief Financial Officer of the Company and Paul Rundell, Chief Restructuring Officer of the Company, ceased to be officers of the Company.
In addition, effective as of the close of business on the Effective Date, Carlos de Solo, Chief Executive Officer of the Company, Alberto de Solo, Chief Operating Officer of the Company, Kevin Wirges, Chief Financial Officer of the Company and Paul Rundell, Chief Restructuring Officer of the Company, ceased to be officers of the Company.
Pursuant to the Plan, effective as of the close of business on the Effective Date, Carlos A. de Solo, Kevin Berg, Edward J. Borkowski, Bryan Cho, Ralph De La Torre, M.D., Dr. Vincent Omachonu, Ryan O’Quinn and Jose R. Rodriguez ceased to be directors of the Company.
Pursuant to the Plan, effective as of the close of business on the Effective Date, Carlos A. de Solo, Kevin Berg, Edward J. Borkowski, Bryan Cho, Ralph De La Torre, M.D., Dr. Vincent Omachonu, Ryan O’Quinn and Jose R. Rodriguez ceased to be directors of the Company.
Pursuant to the Plan, effective as of the close of business on the Effective Date, Carlos A. de Solo, Kevin Berg, Edward J. Borkowski, Bryan Cho, Ralph De La Torre, M.D., Dr. Vincent Omachonu, Ryan O’Quinn and Jose R. Rodriguez ceased to be directors of the Company.
In addition, effective as of the close of business on the Effective Date, Carlos de Solo, Chief Executive Officer of the Company, Alberto de Solo, Chief Operating Officer of the Company, Kevin Wirges, Chief Financial Officer of the Company and Paul Rundell, Chief Restructuring Officer of the Company, ceased to be officers of the Company.
Pursuant to the Plan, effective as of the close of business on the Effective Date, Carlos A. de Solo, Kevin Berg, Edward J. Borkowski, Bryan Cho, Ralph De La Torre, M.D., Dr. Vincent Omachonu, Ryan O’Quinn and Jose R. Rodriguez ceased to be directors of the Company.
Pursuant to the Plan, effective as of the close of business on the Effective Date, Carlos A. de Solo, Kevin Berg, Edward J. Borkowski, Bryan Cho, Ralph De La Torre, M.D., Dr. Vincent Omachonu, Ryan O’Quinn and Jose R. Rodriguez ceased to be directors of the Company.
In addition, effective as of the close of business on the Effective Date, Carlos de Solo, Chief Executive Officer of the Company, Alberto de Solo, Chief Operating Officer of the Company, Kevin Wirges, Chief Financial Officer of the Company and Paul Rundell, Chief Restructuring Officer of the Company, ceased to be officers of the Company.
Pursuant to the Plan, effective as of the close of business on the Effective Date, Carlos A. de Solo, Kevin Berg, Edward J. Borkowski, Bryan Cho, Ralph De La Torre, M.D., Dr. Vincent Omachonu, Ryan O’Quinn and Jose R. Rodriguez ceased to be directors of the Company.
On January 31, 2025, J. Eric Smith, a member of the Company’s board of directors, notified the Company that he was resigning from his role as a director of the Company.
(ii) Luvleen Sidhu, Ajay Asija, and Warren Taylor each resigned as officers
(i) Luvleen Sidhu, John Dolan, Mike Gill, Brent Hurley, Michael Pavone, Aaron Hodari, and Marcy Schwab each resigned from the board of directors
(ii) Luvleen Sidhu, Ajay Asija, and Warren Taylor each resigned as officers
(i) Luvleen Sidhu, John Dolan, Mike Gill, Brent Hurley, Michael Pavone, Aaron Hodari, and Marcy Schwab each resigned from the board of directors
(i) Luvleen Sidhu, John Dolan, Mike Gill, Brent Hurley, Michael Pavone, Aaron Hodari, and Marcy Schwab each resigned from the board of directors
(i) Luvleen Sidhu, John Dolan, Mike Gill, Brent Hurley, Michael Pavone, Aaron Hodari, and Marcy Schwab each resigned from the board of directors
(ii) Luvleen Sidhu, Ajay Asija, and Warren Taylor each resigned as officers
(i) Luvleen Sidhu, John Dolan, Mike Gill, Brent Hurley, Michael Pavone, Aaron Hodari, and Marcy Schwab each resigned from the board of directors
(i) Luvleen Sidhu, John Dolan, Mike Gill, Brent Hurley, Michael Pavone, Aaron Hodari, and Marcy Schwab each resigned from the board of directors
(i) Luvleen Sidhu, John Dolan, Mike Gill, Brent Hurley, Michael Pavone, Aaron Hodari, and Marcy Schwab each resigned from the board of directors
Ryan Weige, the Company’s Grain Merchandiser, was terminated by the Company and hired by a subsidiary of Gevo.
Mr. Crenshaw will replace Westervelt T. “Westy” Ballard, Jr., who has mutually agreed with the Company to terminate his employment as the Company’s President and Chief Executive Officer and to resign his position as a director.
On January 29, 2025 (the “ Separation Date ”), Lourie Zak resigned as Chief Financial Officer of Genelux Corporation (the “ Company ”), effective immediately.
On January 29, 2025, Christopher Sambar notified the Board of Directors (the “Board”) of AST SpaceMobile, Inc. (the “Company”) of his decision to resign as the designee of AT&T Venture Investments, LLC (“AT&T”) from the Board, effective on the same date.
On January 31, 2025, Shelley Webb, Chief Legal & People Officer of PagerDuty, Inc. (the “Company”), notified the Company of her decision to resign from the Company effective February 3, 2025.
Mr. Horlock’s employment shall terminate effective February 28, 2025.
In accordance with the terms and conditions of the Purchase Agreement, effective as of the Closing Date, Chris Toth ceased serving as Executive Vice President and Group President, Kidney Care, and as an executive officer of the Company.
On January 28, 2025, Michael Hurlston notified the Company of his resignation from his position as President and Chief Executive Officer and from the board of directors (the “Board”) of the Company, effective February 3, 2025, to pursue another opportunity.
Jeffrey Maggioncalda, our former President, Chief Executive Officer ( “CEO” ), and a Class III director, in connection with his previously disclosed retirement from those roles effective as of February 3, 2025
On February 1, 2025, Myles Kleeger informed Braze, Inc. (the “Company”) of his intention to resign as President and Chief Commercial Officer of the Company, effective June 1, 2025
Following the appointment of Ms. Calero, Rodolfo Guerrero Angulo resigned as an executive officer and a director of the Company
and Marquez Hernandez Maria De Lourdes resigned as a director of the Company.
Mr. Scott Contino will resign as the Company’s Interim Chief Financial Officer and Principal Financial Officer.
As previously disclosed, Tania Secor, the former Chief Financial Officer of Integral Ad Science Holding Corp. (the “Company”) departed the Company on January 3, 2025.
Effective January 31, 2025, Karthik Sridharan, Senior Executive Vice President and Chief Operations and Technology Officer of Fulton Financial Corporation ("Fulton"), will be leaving Fulton.
On January 30, 2025, Robert Chapek notified the Board of Directors (the “Board”) of Masimo Corporation (“Masimo”) of his irrevocable resignation from the Board and all committees thereof, effective as of the date of the 2025 annual meeting of Masimo, which date the Board has not determined at this time.
On January 29, 2025, the Company notified Salvatore D. Orsini, the Company’s Chief Procurement Officer, that his position was being eliminated resulting in the termination of his employment with the Company, effective February 28, 2025.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.